No Data
Anhui Anke Biotechnology (Group) Co., Ltd.'s (SZSE:300009) Stock Is Going Strong: Is the Market Following Fundamentals?
Anhui Anke Biotechnology (300009.SZ): The application for new indications of human growth hormone injection has been accepted.
On November 25, Glonghui reported that anhui anke biotechnology (300009.SZ) announced that recently, anhui anke biotechnology engineering (group) co., ltd. received the administrative license document "Acceptance Notice" from the National Medical Products Administration. The company's supplemental application for the indication of human growth hormone injection for small for gestational age (SGA) was accepted, with acceptance number: CYSB2400303. The goal of human growth hormone treatment for SGA is to accelerate the completion of catch-up growth in early childhood linear growth and to sustain growth during late childhood development.
Anhui Anke Biotechnology (300009.SZ): The controlling shareholder, actual controller, and some directors and executives intend to reduce their shareholding in the company.
Glory Exchange reported on November 20th that anhui anke biotechnology (300009.SZ) announced that the actual controller, controlling shareholder, director, and senior manager Song Lihua, controlling shareholder, actual controller, and director Song Liming, as well as director and senior manager Zhao Hui plan to reduce their shareholding in the company. Song Lihua plans to reduce 12 million shares, accounting for 0.72% of the company's total share capital; Song Liming plans to reduce 4 million shares, accounting for 0.24% of the company's total share capital; Zhao Hui plans to reduce 0.2 million shares, accounting for 0.01% of the company's total share capital. The methods of reduction include centralized bidding and block trades, and the reduction period is fifteen days from the date of announcement.
Retail Investors Among Anhui Anke Biotechnology (Group) Co., Ltd.'s (SZSE:300009) Largest Stockholders and Were Hit After Last Week's 4.4% Price Drop
Anke Biotech: Report for the third quarter of 2024
Anhui Anke Biotechnology (300009.SZ) released its performance for the first three quarters, with a net income of 0.59 billion yuan, a year-on-year decrease of 9.89%.
Anhui Anke Biotechnology (300009.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue...
Anhui Anke Biotechnology (Group) Co., Ltd. (SZSE:300009) Looks Inexpensive But Perhaps Not Attractive Enough
